Clinical Trial Update: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating the safety and tolerability of Nivolumab alone or in combination with Relatlimab or Ipilimumab i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Relatlimab (relatlimab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Dan Zandberg | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING